November 1, 2017 05:54 AM EDT
R&D

As­traZeneca’s asth­ma drug tralok­inum­ab goes 0 for 3 in PhI­II as 2 more tri­als flop

John Carroll

Editor & Founder

You can write off just about all of the re­main­ing val­ue as­signed to As­traZeneca’s asth­ma drug tralok­inum­ab — if you hadn’t al­ready done so. Out­side of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times